Exelixis (EXEL) Receives EC Approval of CABOMETYX as RCC Treatment Following VEGF-Targeted Therapy
Tweet Send to a Friend
Exelixis, Inc. (Nasdaq: EXEL) announced that the European Commission (EC) has approved CABOMETYX (cabozantinib) tablets for the treatment of advanced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
